Empagliflozin and cardiovascular outcomes in type 2 diabetes
نویسندگان
چکیده
منابع مشابه
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
BACKGROUND The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovas...
متن کاملCardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard tr...
متن کاملEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
803 of coronary narrowing. These people were randomized to either placebo or a drug called empagliflozin, and they were actually randomized to 2 different doses of empagliflozin, either 10 mg or 25 mg. The primary analysis was to compare the placebo group to the combined both-doses group. The study continued for 3.1 years, patients were seen periodically, and as I said, it was a blinded study, ...
متن کاملEmpagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
BACKGROUND AND PURPOSE In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse cardiovascular events, driven by a reduction in cardiovascular mortality, with no significant differen...
متن کاملGlycosylated Hemoglobin and Cardiovascular Outcomes in Type 2 Diabetes
This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisherauthenticated version will be available in a future issue of Diabetes Care in pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Cardiology
سال: 2015
ISSN: 1759-5002,1759-5010
DOI: 10.1038/nrcardio.2015.183